Your session is about to expire
← Back to Search
Imaging with 18F-FMAU for Brain Cancer
Phase < 1
Waitlist Available
Led By Hossein Jadvar, MD
Research Sponsored by University of Southern California
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Documented history of either primary brain tumor (e.g. glioma) or metastatic brain tumor from another primary cancer (e.g. lung, breast, colon, melanoma, kidney)
Documented radiation therapy regardless of treatments prior to radiation therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights
Study Summary
This trial is testing a new way to image brain tumors using a radioactive tracer. The tracer is given through a vein and helps doctors take pictures of the inside of the body. This may help them find the tumor and see how far the disease has spread.
Who is the study for?
This trial is for adults over 18 with a history of brain tumors, whether originating in the brain or spread from cancers like lung, breast, colon, melanoma, or kidney. Participants must have undergone radiation therapy and be able to stay still during imaging without issues from claustrophobia or seizures.Check my eligibility
What is being tested?
The study tests a radioactive tracer called 18F-FMAU used in PET/CT scans alongside MRI to improve detection and diagnosis of brain tumors. It aims to see if this method can better locate cancer and assess its spread within the brain.See study design
What are the potential side effects?
Potential side effects may include reactions to the tracer such as mild irritation at injection site or allergic reaction. The MRI procedure might cause discomfort for those with claustrophobia despite it being an exclusion criterion.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have a history of a brain tumor, either primary or spread from another cancer.
Select...
I have received radiation therapy for my condition.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Correlation between multiparametric magnetic resonance imaging (mpMRI) radiomics and dynamic fluorine F 18 (18F)-FAMU (FMAU) positron emission tomography (PET) kinetic analysis parameters
Different pattern in radiomics mpMRI and FMAU PET kinetic analysis parameters
Trial Design
1Treatment groups
Experimental Treatment
Group I: Diagnostic (18F-FMAU, PET/CT, mpMRI)Experimental Treatment4 Interventions
Patients receive 18F-FMAU intravenously (IV) and undergo a PET/CT scan over 60 minutes. Patients then undergo standard of care mpMRI over approximately 45 minutes.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Computed Tomography
2017
Completed Phase 2
~2720
Positron Emission Tomography
2008
Completed Phase 2
~2240
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
13,654 Previous Clinical Trials
40,933,143 Total Patients Enrolled
University of Southern CaliforniaLead Sponsor
905 Previous Clinical Trials
1,596,308 Total Patients Enrolled
Hossein Jadvar, MDPrincipal InvestigatorUniversity of Southern California
2 Previous Clinical Trials
275 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have a history of a brain tumor, either primary or spread from another cancer.You are afraid of small, enclosed spaces.I cannot stay still during scans.I am unable to understand and give consent for treatment.You have a medical implant that can't be used during magnetic resonance imaging (MRI).I am older than 18 years.I have received radiation therapy for my condition.I have seizures that don't respond to treatment.
Research Study Groups:
This trial has the following groups:- Group 1: Diagnostic (18F-FMAU, PET/CT, mpMRI)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is this research initiative available for participants at the moment?
"Clinicaltrials.gov shows that this medical investigation is seeking volunteers, having first been posted on February 15th 2021 and last updated on August 19th 2022."
Answered by AI
What is the total enrollment number for this medical experiment?
"Affirmative. Clinicaltrials.gov hosts information that reveals this study is actively looking for participants, which was first announced on February 15th 2021 and most recently updated nearly a year later in August 19th 2022. 10 patients are required to be recruited from just one medical centre."
Answered by AI
What precedent has been set by previous research involving Multiparametric Magnetic Resonance Imaging?
"Currently, two clinical trials that use Multiparametric Magnetic Resonance Imaging are underway. However, neither of these investigations have reached the Phase 3 stage yet. Moreover, most of the studies conducted for this medical technique take place in Los Angeles but there are also two other research centres involved."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger